KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Non-Current Deffered Revenue (2022 - 2024)

Opko Health (OPK) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $7000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Non-Current Deffered Revenue fell 94.85% year-over-year to $7000.0, compared with a TTM value of $7000.0 through Sep 2024, down 94.85%, and an annual FY2023 reading of $7000.0, down 94.93% over the prior year.
  • Non-Current Deffered Revenue was $7000.0 for Q3 2024 at Opko Health, roughly flat from $7000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $140000.0 in Q2 2023 and bottomed at $7000.0 in Q4 2023.
  • Average Non-Current Deffered Revenue over 3 years is $63142.9, with a median of $7000.0 recorded in 2023.
  • Peak annual rise in Non-Current Deffered Revenue hit 94.85% in 2024, while the deepest fall reached 95.0% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $138000.0 in 2022, then tumbled by 94.93% to $7000.0 in 2023, then changed by 0.0% to $7000.0 in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for OPK at $7000.0 in Q3 2024, $7000.0 in Q2 2024, and $7000.0 in Q1 2024.